FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994555743> ?p ?o ?g. }

• W1994555743 abstract "Background: The HER2 gene has been established as a valid biomarker in the treatment of breast cancer patients with trastuzumab and probably with other agents, such as paclitaxel or anthracyclines. The TOP2A gene has been associated with response to anthracyclines. The relationship of HER2/TOP2A gene status in the presence of CEP17 polysomy with patients’ outcome following adjuvant treatment with anthracyclines with or without paclitaxel is not established. Patients and methods: Formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks from 1,033 patients (61.5% of 1,681 randomized patients) with high-risk operable breast cancer enrolled in two sequential phase III trials 1,2 were assessed in a central laboratory for HER2/TOP2A gene amplification and CEP17 polysomy by fluorescence in situ hybridization (FISH) and tumors were categorized according to the 2007 American Society of Clinical Oncology/College of American Pathologists guidelines. HER2 and TOP2A amplification was defined as a gene/CEP17 ratio of >=2.2 and >=2.0, respectively or a gene copy number of >6. Additionally HER2, TOP2A, ER/PgR, Ki67, CK5 and EGFR protein expression were assessed by immunohistochemistry (IHC) and all patients were classified according to their IHC phenotype. Treatment consisted of epirubicin-based dose-dense sequential adjuvant chemotherapy followed by hormonal therapy and radiation, as indicated. Results: Disease-free survival (DFS) and overall survival (OS) did not differ significantly between treatment groups. Median follow-up was 92 months, while 5-year DFS (OS) rates were 74% (88%), 69% (81%) and 75% (86%) for the E-T-CMF, E-CMF and ET-CMF groups, respectively. HER2 amplification was found in 24.1% of the patients and TOP2A amplification in 10.3%. In total, 46.7% of HER2 amplified tumors demonstrated TOP2A co-amplification. The median (range) of HER2, TOP2A and CEP17 copy numbers was 2.55 (0.70−45.15), 2.2 (0.50−26.15) and 2.05 (0.45−26.55), respectively. 21% of the tumors were considered to be polysomic (32.5% of those with HER2 amplification). Adjusting for treatment groups in the Cox model, TOP2A amplification, CEP17 polysomy and HER2/TOP2A co-amplification were not associated with either relapse or death. Treatment with paclitaxel was associated with improved survival in the HER2−amplified subgroup (HR=0.493, interaction p=0.036; adjusting for clinicopathological prognostic factors: HR=0.553, interaction p=0.054), an association that was not apparent for DFS. Conclusions: HER2 amplification was predictive for OS benefit from adjuvant treatment with paclitaxel in patients treated with epirubicin-based dose-dense sequential adjuvant chemotherapy, but not for DFS. TOP2A amplification, CEP17 polysomy and HER2/TOP2A co-amplification were not associated with outcome. 1. Ann Oncol 16:1762–71, 2005; 2. Ann Oncol 19:853–60, 2008. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD05-02." @default.
• W1994555743 created "2016-06-24" @default.
• W1994555743 creator A5001684767 @default.
• W1994555743 creator A5005181965 @default.
• W1994555743 creator A5005730021 @default.
• W1994555743 creator A5012112204 @default.
• W1994555743 creator A5015478637 @default.
• W1994555743 creator A5026455816 @default.
• W1994555743 creator A5036385408 @default.
• W1994555743 creator A5041575636 @default.
• W1994555743 creator A5048212045 @default.
• W1994555743 creator A5055480892 @default.
• W1994555743 creator A5055539716 @default.
• W1994555743 creator A5063001042 @default.
• W1994555743 creator A5084537623 @default.
• W1994555743 creator A5090633646 @default.
• W1994555743 date "2011-12-15" @default.
• W1994555743 modified "2023-09-25" @default.
• W1994555743 title "PD05-02: Effect of HER2/Topoisomerase II alpha (TOP2A) Gene Status or Protein Expression and Chromosome 17 (CEP17) Polysomy on the Outcome of Breast Cancer Patients Treated with Anthracycline-Containing Dose-Dense Sequential Adjuvant Chemotherapy with or without Paclitaxel – A Pooled Analysis of Two Hellenic Cooperative Oncology Group (HeCOG) Phase III Trials." @default.
• W1994555743 doi "https://doi.org/10.1158/0008-5472.sabcs11-pd05-02" @default.
• W1994555743 hasPublicationYear "2011" @default.
• W1994555743 type Work @default.
• W1994555743 sameAs 1994555743 @default.
• W1994555743 citedByCount "1" @default.
• W1994555743 countsByYear W19945557432013 @default.
• W1994555743 crossrefType "proceedings-article" @default.
• W1994555743 hasAuthorship W1994555743A5001684767 @default.
• W1994555743 hasAuthorship W1994555743A5005181965 @default.
• W1994555743 hasAuthorship W1994555743A5005730021 @default.
• W1994555743 hasAuthorship W1994555743A5012112204 @default.
• W1994555743 hasAuthorship W1994555743A5015478637 @default.
• W1994555743 hasAuthorship W1994555743A5026455816 @default.
• W1994555743 hasAuthorship W1994555743A5036385408 @default.
• W1994555743 hasAuthorship W1994555743A5041575636 @default.
• W1994555743 hasAuthorship W1994555743A5048212045 @default.
• W1994555743 hasAuthorship W1994555743A5055480892 @default.
• W1994555743 hasAuthorship W1994555743A5055539716 @default.
• W1994555743 hasAuthorship W1994555743A5063001042 @default.
• W1994555743 hasAuthorship W1994555743A5084537623 @default.
• W1994555743 hasAuthorship W1994555743A5090633646 @default.
• W1994555743 hasConcept C104317684 @default.
• W1994555743 hasConcept C121608353 @default.
• W1994555743 hasConcept C126322002 @default.
• W1994555743 hasConcept C142724271 @default.
• W1994555743 hasConcept C143998085 @default.
• W1994555743 hasConcept C167752854 @default.
• W1994555743 hasConcept C204232928 @default.
• W1994555743 hasConcept C2776802502 @default.
• W1994555743 hasConcept C2777292972 @default.
• W1994555743 hasConcept C2777542201 @default.
• W1994555743 hasConcept C2779786085 @default.
• W1994555743 hasConcept C2780835546 @default.
• W1994555743 hasConcept C2781303241 @default.
• W1994555743 hasConcept C30481170 @default.
• W1994555743 hasConcept C502942594 @default.
• W1994555743 hasConcept C530470458 @default.
• W1994555743 hasConcept C55493867 @default.
• W1994555743 hasConcept C71924100 @default.
• W1994555743 hasConcept C86803240 @default.
• W1994555743 hasConceptScore W1994555743C104317684 @default.
• W1994555743 hasConceptScore W1994555743C121608353 @default.
• W1994555743 hasConceptScore W1994555743C126322002 @default.
• W1994555743 hasConceptScore W1994555743C142724271 @default.
• W1994555743 hasConceptScore W1994555743C143998085 @default.
• W1994555743 hasConceptScore W1994555743C167752854 @default.
• W1994555743 hasConceptScore W1994555743C204232928 @default.
• W1994555743 hasConceptScore W1994555743C2776802502 @default.
• W1994555743 hasConceptScore W1994555743C2777292972 @default.
• W1994555743 hasConceptScore W1994555743C2777542201 @default.
• W1994555743 hasConceptScore W1994555743C2779786085 @default.
• W1994555743 hasConceptScore W1994555743C2780835546 @default.
• W1994555743 hasConceptScore W1994555743C2781303241 @default.
• W1994555743 hasConceptScore W1994555743C30481170 @default.
• W1994555743 hasConceptScore W1994555743C502942594 @default.
• W1994555743 hasConceptScore W1994555743C530470458 @default.
• W1994555743 hasConceptScore W1994555743C55493867 @default.
• W1994555743 hasConceptScore W1994555743C71924100 @default.
• W1994555743 hasConceptScore W1994555743C86803240 @default.
• W1994555743 hasLocation W19945557431 @default.
• W1994555743 hasOpenAccess W1994555743 @default.
• W1994555743 hasPrimaryLocation W19945557431 @default.
• W1994555743 isParatext "false" @default.
• W1994555743 isRetracted "false" @default.
• W1994555743 magId "1994555743" @default.
• W1994555743 workType "article" @default.